Groups | MMP-7 (ng/ml) | TIMP-1 (ng/ml) | HE4 (pmol/L) | CA125 (U/ml) | |
---|---|---|---|---|---|
Ovarian cancer Median Range | Stage I | a, b4.76 1.98–17.86 | a108.35 4.60–328.90 | a, b118.70 34.50–1093.80 | a66.73 10.60–557.20 |
Stage II | a, b4.73 2.24–18.00 | 151.70 15.20–839.00 | a, b120.90 38.30–1205.70 | a, b61.45 9.80–2060.78 | |
Stage III | a, b, d7.92 1.98–17.80 | a, b, d241.20 26.00–554.70 | a, b, d650.55 48.70–1810.60 | a, b, d766.20 10.10–2742.00 | |
Stage IV | a, b, d12.27 2.00–27.40 | a, b, d252.60 28.00–642.00 | a, b372.95 37.80–1944.20 | a, b, d541.13 14.30–8602.30 | |
Total group | a, b5.60 1.98–27.40 | a, b170.79 4.60–839.00 | a, b207.09 34.50–1944.20 | a, b139.70 9.80–8602.30 | |
Control groups Median Range | Benign ovarian tumor total group | 3.18 1.33–24.25 | 107.00 6.71–309.06 | 57.70 34.90–202.90 | c22.90 5.80–748.00 |
Healthy subjects | 3.25 1.75–8.42 | 128.88 23.38–266.09 | 54.00 15.00–408.89 | 12.70 1.49–36.60 |